Placebo News and Research

RSS

SAMe dietary supplement effective for major depressive disorders: Study

A new study conducted by investigators at Harvard Medical School and Massachusetts General Hospital (MGH) suggests that S-Adenosyl Methionine (SAMe), an over-the-counter dietary supplement, can be an effective, relatively well-tolerated, adjunctive treatment for adults with major depressive disorders who do not respond to their treatment with antidepressant medication.

2 Sep 2010

Martek Biosciences 2010 third quarter revenue increases 51% to $117.2 million

Martek Biosciences Corporation today announced its financial results for the third quarter of fiscal 2010.

2 Sep 2010

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting about 7 million people in Europe. It is a progressive chronic disease in which episodes become more frequent and long-lasting over time. Conventional anti-arrhythmic therapy aims at halting progression and reducing symptoms, but the use of most anti-arrhythmic drugs is compromised by severe side effects, such as pro-arrhythmia or extra-cardiac organ toxicity.

31 Aug 2010

Bionovo receives positive guidance for Menerba drug candidate

Bionovo, Inc. announced today that it has received positive guidance from the U.S. Food and Drug Administration (FDA) regarding the Company's Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate Menerba.

31 Aug 2010

Bioheart's MyoCell adult stem cell therapy shows effective for heart failure patients: Study

Bioheart, Inc., The mission of the Cell Therapy Foundation is to improve public health through the support of effective adult stem cell research and education. The Foundation aims to promote basic and applied knowledge, processes and cell therapies.

31 Aug 2010

Study shows statin therapy not associated with cancer

In the largest and most reliable study of its type, the University of Oxford (UK) and the University of Sydney (Australia) have demonstrated that statin therapy is not a cause of increased cancer rates and deaths. The conclusions of this study will reassure the millions of people worldwide who are taking statins to lower cholesterol levels, and clarifies earlier research that had raised concerns of a causal link.

31 Aug 2010

Study: IV ibuprofen decreases pain, morphine use in pre and post-operative orthopedic surgery patients

Cumberland Pharmaceuticals Inc. today announced the publication of new data supporting the safety and efficacy of Caldolor® (ibuprofen) Injection in pre and post-operative orthopedic surgery patients. The study, which was published in the August edition of the peer-reviewed journal Pain Medicine, concludes that IV ibuprofen significantly decreased pain and morphine use when compared with placebo.

31 Aug 2010

Genetic profiling to predict treatment benefits of ACE inhibitor therapy for CAD

The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.

31 Aug 2010

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

Aspirin and thienopyridine antiplatelet therapy (such as clopidogrel) are standard care in the treatment of acute coronary syndrome (ACS) and even in stable coronary artery disease (CAD) after coronary intervention with stent. However, effective antiplatelet agents are needed which do not increase the risk of bleeding.

31 Aug 2010

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation.

31 Aug 2010

Smoked cannabis relieves chronic neuropathic pain

The medicinal use of cannabis has been debated by clinicians, researchers, legislators and the public at large for many years as an alternative to standard pharmaceutical treatments for pain, which may not always be effective and may have unwanted side effects. A new study by McGill University Health Centre (MUHC) and McGill University researchers provides evidence that cannabis may offer relief to patients suffering from chronic neuropathic pain.

30 Aug 2010

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

BioDelivery Sciences International, Inc. announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session.

30 Aug 2010

Selective lowering of heart rate reduces risk of death and hospitalization: Study

The results of a major international study presented at the European Society of Cardiology Congress in Stockholm and published simultaneously in The Lancet show, for the first time, that selectively lowering heart rate with a novel medication, ivabradine, significantly reduces risk of death and hospitalization for patients with heart failure. This also resolves a longstanding debate about whether lowering heart rate itself can actually lower the risk of heart disease progression.

30 Aug 2010

Low doses of n-3 fatty acids do not reduce overall rate of major cardiovascular events

Results from the Alpha Omega Trial, a multicentre, placebo-controlled trial in men and women following myocardial infarction (MI), suggest that low doses of n-3 fatty acids given in the form of enriched margarines do not reduce the overall rate of major cardiovascular events.

30 Aug 2010

RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients

Results from a recent phase 2b clinical trial may provide a new approach to managing excess potassium levels in patients with heart failure and heart failure with chronic kidney disease.

30 Aug 2010

SHIFT study finds Ivabradine reduces heart failure risk

Ivabradine, a selective If inhibitor already investigated for its effects in coronary artery disease and left ventricular dysfunction, significantly lowers the risk of heart failure, according to results of the SHIFT study (Systolic Heart failure treatment with the If inhibitor ivabradine Trial).

30 Aug 2010

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

Forest Laboratories reveals top-line results from cariprazine Phase II clinical trial for bipolar depression

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of bipolar depression. Cariprazine is currently undergoing Phase III trials for separate indications of schizophrenia and bipolar mania.

30 Aug 2010

Researchers find smoked cannabis reduces chronic neuropathic pain

For people suffering chronic pain, smoked cannabis reduces pain, improves mood and helps sleep, according to new research published in CMAJ.

30 Aug 2010

TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients

Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial.

30 Aug 2010

Placebo News and Research

SAMe dietary supplement effective for major depressive disorders: Study

Martek Biosciences 2010 third quarter revenue increases 51% to $117.2 million

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

Bionovo receives positive guidance for Menerba drug candidate

Bioheart's MyoCell adult stem cell therapy shows effective for heart failure patients: Study

Study shows statin therapy not associated with cancer

Study: IV ibuprofen decreases pain, morphine use in pre and post-operative orthopedic surgery patients

Genetic profiling to predict treatment benefits of ACE inhibitor therapy for CAD

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Smoked cannabis relieves chronic neuropathic pain

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

Selective lowering of heart rate reduces risk of death and hospitalization: Study

Low doses of n-3 fatty acids do not reduce overall rate of major cardiovascular events

RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients

SHIFT study finds Ivabradine reduces heart failure risk

Latest achievements in brain research and treatment for mental disorders

Forest Laboratories reveals top-line results from cariprazine Phase II clinical trial for bipolar depression

Researchers find smoked cannabis reduces chronic neuropathic pain

TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News